S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$162.47
-4.72 (-2.82%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$160.61
$165.99
50-Day Range
$116.09
$174.69
52-Week Range
$114.86
$293.20
Volume
240,100 shs
Average Volume
300,693 shs
Market Capitalization
$6.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$218.78

Penumbra MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
34.7% Upside
$218.78 Price Target
Short Interest
Healthy
5.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.20mentions of Penumbra in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$355,536 Sold Last Quarter
Proj. Earnings Growth
352.00%
From $0.25 to $1.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

178th out of 1,116 stocks

Surgical & Medical Instruments Industry

14th out of 112 stocks

PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Wall Street Analyst Weigh In

PEN has been the topic of a number of research reports. William Blair reissued an "outperform" rating on shares of Penumbra in a research note on Tuesday, May 3rd. TheStreet cut Penumbra from a "c-" rating to a "d+" rating in a report on Tuesday, July 12th. Truist Financial decreased their target price on Penumbra to $180.00 in a report on Friday, July 22nd. BTIG Research decreased their target price on Penumbra from $272.00 to $213.00 and set a "buy" rating on the stock in a report on Monday, July 18th. Finally, Canaccord Genuity Group decreased their target price on Penumbra from $244.00 to $189.00 and set a "buy" rating on the stock in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $218.78.

Penumbra Stock Down 0.6 %

Shares of PEN Stock traded down $1.01 on Friday, reaching $167.19. 165,915 shares of the company's stock traded hands, compared to its average volume of 439,108. Penumbra has a 12-month low of $114.86 and a 12-month high of $293.20. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 4.93. The company has a market capitalization of $6.33 billion, a P/E ratio of -321.51 and a beta of 0.73. The business's 50 day moving average price is $136.91 and its two-hundred day moving average price is $171.76.

Penumbra (NYSE:PEN - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.07. Penumbra had a positive return on equity of 0.97% and a negative net margin of 2.40%. The business had revenue of $208.30 million for the quarter, compared to the consensus estimate of $206.24 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. Penumbra's revenue for the quarter was up 13.0% compared to the same quarter last year. On average, equities analysts forecast that Penumbra will post 0.25 earnings per share for the current year.

Insider Buying and Selling at Penumbra

In other Penumbra news, Director Thomas Wilder sold 248 shares of the business's stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $123.64, for a total value of $30,662.72. Following the transaction, the director now owns 462 shares in the company, valued at $57,121.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Penumbra news, Director Thomas Wilder sold 248 shares of the business's stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $123.64, for a total value of $30,662.72. Following the completion of the sale, the director now owns 462 shares of the company's stock, valued at $57,121.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Johanna Roberts sold 1,700 shares of the business's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $175.04, for a total value of $297,568.00. Following the completion of the sale, the executive vice president now directly owns 55,496 shares of the company's stock, valued at approximately $9,714,019.84. The disclosure for this sale can be found here. Insiders have sold 2,151 shares of company stock worth $355,536 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Penumbra (NYSE:PEN) Trading Up 10.5% After Strong Earnings
Penumbra (NYSE:PEN) Shares Up 10.5% on Strong Earnings
Penumbra (PEN) to Release Earnings on Thursday
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
8/04/2022
Today
8/19/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$218.78
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$163.00
Forecasted Upside/Downside
+34.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$5.28 million
Pretax Margin
-4.89%

Debt

Sales & Book Value

Annual Sales
$747.59 million
Cash Flow
$1.10 per share
Book Value
$25.60 per share

Miscellaneous

Free Float
35,804,000
Market Cap
$6.16 billion
Optionable
Optionable
Beta
0.73

Key Executives

  • Mr. Adam ElsesserMr. Adam Elsesser (Age 60)
    Co-Founder, Chairman, Pres & CEO
    Comp: $497.79k
  • Dr. Arani Bose M.D. (Age 60)
    Co-Founder & Director
  • Ms. Maggie S. Yuen (Age 50)
    Chief Financial Officer
    Comp: $616.3k
  • Mr. Lambert Shiu (Age 42)
    Chief Accounting Officer
    Comp: $468.76k
  • Ms. Johanna RobertsMs. Johanna Roberts (Age 50)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $608.84k
  • Ms. Lynn Rothman (Age 61)
    Exec. VP & Chief Bus. Officer
    Comp: $605.5k
  • Mr. Ben Sorci
    Exec. VP of Operations
  • Mr. Pankaj Tiwari
    Exec. VP & Chief Information Officer
  • Ms. Jee Hamlyn-Harris
    Investor Relations Officer
  • Ms. Shruthi Narayan
    Director of Marketing - Vascular













PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2022?

9 analysts have issued 1 year target prices for Penumbra's shares. Their PEN share price forecasts range from $163.00 to $300.00. On average, they predict the company's stock price to reach $218.78 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2022?

Penumbra's stock was trading at $287.32 on January 1st, 2022. Since then, PEN shares have decreased by 43.5% and is now trading at $162.47.
View the best growth stocks for 2022 here
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) announced its quarterly earnings results on Thursday, August, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.07. The company had revenue of $208.30 million for the quarter, compared to the consensus estimate of $206.24 million. Penumbra had a positive trailing twelve-month return on equity of 0.97% and a negative net margin of 2.40%. The business's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.21 earnings per share.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2022 earnings guidance on Thursday, August, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $860.00 million-$875.00 million, compared to the consensus revenue estimate of $869.01 million.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (14.92%), Baillie Gifford & Co. (3.38%), Price T Rowe Associates Inc. MD (3.25%), Clearbridge Investments LLC (2.69%), William Blair Investment Management LLC (2.58%) and State Street Corp (2.56%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $162.47.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $6.16 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Penumbra have?

The company employs 3,800 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.